Thailand’s economy expanded at a slower pace than forecast, as a slump in exports and a political impasse

Senate Majority Leader Chuck Schumer has called on the US Food and Drug Administration to investigate the high caffeine content of PRIME Energy drinks, which he claims are being targeted to children as "one of the summer's hottest beverages for kids."

A new iMac—and possibly new MacBook Pros—may arrive as early as this month. Apple’s last

Meta has released a host of new features to increase parental supervision and elevate safety

A South Carolina judge has temporarily blocked the state's new abortion restrictions from going into effect, just one day after the governor signed them into law.

A much-feared backup of U.S. passport applications has snarled summer plans for would-be travelers around the world

Rarely has a film gotten a full-body reaction out of me like First Time Female

A spacecraft orbiting Mars has captured evidence of the Red Planet's dramatic past. The European

Sergio Perez has dismissed rumours he may retire from Formula 1 and insists he wants to continue in the sport for “at least three to four more years.” The Red Bull driver is second in the 2023 F1 world championship standings behind world champion Max Verstappen but is now only 30 points ahead of third-placed Lewis Hamilton, having not won a race in the best car on the grid since April. The 33-year-old has particularly struggled since the summer break, scoring just five points in his last three races. Perez’s poor run of form has fuelled speculation about his seat for 2024. He has a contract until the end of next season, but rumours have sprung up that the Mexican may it call it a day at the end of this season, especially if Red Bull have told him behind closed doors that he won’t keep his seat. However, Perez has moved to squash those rumours and, having been a permanent fixture on the grid since the 2011 season, sees himself in the sport for more years to come. “Well, right now, I have a contract for next year – and it will be important to have a good year,” Perez said, as reported by Planet F1. “I have the motivation to continue and I want to stay for more years because I believe that I still have a lot to give in Formula 1. “I would like to stay in F1 for at least three to four more years.” Perez will be eyeing an improved run of form in the forthcoming triple-header, with his home race in Mexico City sandwiched in-between Austin and Sao Paulo. This weekend’s US Grand Prix is also the penultimate sprint weekend of the season, giving the grid another opportunity to attain valuable points. Read More Nicolas Hamilton: ‘Lewis has never put a penny into my racing... it’s not easy being related to him’ McLaren confirm first female driver in development programme Daniel Ricciardo to make F1 return from injury at United States Grand Prix

With new research emerging, more questions have been raised about weight-loss injections, how they work, and the risks involved. Here are some of your questions answered. What are weight loss injections? Championed by some celebrities, including Elon Musk, weight loss injections were originally created to treat people with type 2 diabetes and other weight-related health issues. They are a type of prescription-based medical treatment that interferes with your metabolism, regulates your appetite and as a result encourages weight loss. The drugs belong to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, which mimic the GLP-1 hormone, released in the gut after eating some food. The only FDA-approved stomach injections to help with weight management are semaglutide — sold under the brand names Ozempic, Wegovy and Rybelsus — and liraglutide — sold under Saxenda. But others are in development. Helen Knight, programme director of the Centre for Health Technology Evaluation at the National Institute for Health and Care Excellence (Nice) said: “We know that management of overweight and obesity is one of the biggest challenges our health service is facing with nearly two-thirds of adults either overweight or obese. It is a lifelong condition that needs medical intervention, has psychological and physical effects, and can affect the quality of life. “But in recent years Nice has been able to recommend a new line of pharmaceutical treatments which have shown that those people using them, alongside changes to their diet and exercise, have been able to reduce their weight.” How do they work? According to Nice’s independent appraisal committee, drugs like semaglutide should only be prescribed to patients as an alternative for weight management — alongside a reduced-calorie diet and increased physical activity in adults. They should also have a BMI of at least 35.0 kg/m2 (this is medically classified as obese), and especially, to people with a BMI of 30.0 kg/m2 to 34.9 kg/m2, have non-diabetic hyperglycaemia (blood sugar that is above normal but below those needed to diagnose diabetes) or are at high risk of other weight-related conditions such as strokes and heart attacks, due to other factors such as high blood pressure and high cholesterol. Using semaglutide as an example, a typical dose for weight loss is 2.4 milligrams, administered weekly as under-the-skin self-injections. How are they going to be rolled out? Nice formally recommended liraglutide, orlistat and semaglutide as medicines suitable to use for weight loss earlier this year. And with such drugs also available through online pharmacies by private prescription, a growing number of people have tried the jabs. If they are prescribed alongside a reduced-calorie diet, increased physical activity, and behavioural support, after a year, people taking them can lose up to 15% of their body weight, with results visible within the first month, according to the Nice clinical trials. Some weight loss injections are available on the NHS, but they are only prescribed under certain circumstances. Following an announcement of a £40 million two-year pilot on June 7, the government have said more people living with obesity will have access to the newest and most effective obesity drugs to help cut NHS waiting lists. What are the possible side effects? Europe’s drug regulator The European Medicines Agency (EMA) is investigating whether patients using some weight loss and obesity jabs are at risk of suicidal thoughts and thoughts of self-harm, which highlights some of the controversy surrounding the phenomenon. The EMA safety committee said it is looking at cases among people who use a semaglutide or liraglutide-containing medicine for weight loss – where “signals” were raised by the Icelandic Medicines Agency. “A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation,” the EMA said. “The case reports included two cases of suicidal thoughts, one following the use of Saxenda and one after Ozempic. One additional case reported thoughts of self-injury with Saxenda. “The semaglutide-containing medicine Wegovy and the liraglutide-containing medicine Saxenda are authorised for weight loss, together with diet and physical activity. “Suicidal behaviour is not currently listed as a side-effect in the EU product information of these medicines.” If you have a history of medullary thyroid cancer, gallbladder disease, or even pancreatitis, you should avoid taking weight loss injections like semaglutide. People who do take the prescription drug for weight loss sometimes experience dizziness, fatigue, and gastrointestinal issues — the most common side effects among patients — such as diarrhoea, constipation and gassiness. They are also at risk of getting headaches and stomach conditions including vomiting, bloating and nausea. Read More Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live Journalist and author Yomi Adegoke on the real-life consequences of social media What is group B strep? Charity says pregnant women ‘in the dark’ Britney Spears: I worked my ass off to get my memoir written

In France's southern Bordeaux region, the grape harvest is often now done at night to ensure the peak freshness required to obtain the best wine but this is...

BELLEVUE, Wash.--(BUSINESS WIRE)--Jun 26, 2023--